Is GLUE or LENZ more undervalued in 2026?

CirclFi compares Monte Rosa Therapeutics, Inc. (GLUE) and LENZ Therapeutics, Inc. (LENZ) using 13 institutional-grade valuation models. GLUE has a Quality of Company score of 5.2/10 while LENZ scores 5.3/10.

Which is a better buy — GLUE or LENZ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GLUE and LENZ valuations compare?

GLUE at $19.39 and LENZ at $7.99 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GLUE vs LENZ Valuation Comparison 2026 — Intrinsic Value Analysis

GLUE

Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

SAFE

Price

$19.39

Last close

Models

12/13

Active

LENZ

Biological Products, (No Diagnostic Substances)

LENZ Therapeutics, Inc.

Quality

5.3

out of 10

Value Trap

SAFE

Price

$7.99

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	GLUE Fair Value	GLUE Upside	LENZ Fair Value	LENZ Upside
Bayesian DCF	Intrinsic	$5.96	-69.3%	$2.33	-70.8%
Earnings Power Value	Intrinsic	$3.72	-80.2%	$2.46	-72.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GLUE vs LENZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GLUE vs LENZ — Which Stock Is More Undervalued?

LENZ scores higher with a 5.3/10 quality rating vs GLUE's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Monte Rosa Therapeutics, Inc. (GLUE) and LENZ Therapeutics, Inc. (LENZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GLUE currently trades at $19.39 with a QOC of 5.2/10, while LENZ trades at $7.99 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).